Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02293382 · ClinicalTrials.gov registry record
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 30
- Enrollment target
NCT02293382: Completed study, sponsored by Alexion Pharmaceuticals.
NCT02293382 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02293382 has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The objective is to perform a retrospective chart review to generate data to evaluate the clinical characteristics and course of disease progression of MPS IIIB.
Primary Outcome
Data obtained by retrospective chart review will include medical history data including patient demographics, disease manifestation onset, clinical history, diagnostic tests and treatments for MPS IIIB, supportive interventions/medications, clinical chemistry and haematology results, anthropometric data, radiology results, and autopsy findings.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-01 |
What the finished NCT02293382 record still lists
NCT02293382 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02293382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02293382 about?
NCT02293382 is a clinical study titled "A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB". The objective is to perform a retrospective chart review to generate data to evaluate the clinical characteristics and course of disease progression of MPS IIIB.
What is the current status of trial NCT02293382?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-07. Estimated completion is 2015-01.
Who is sponsoring clinical trial NCT02293382?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia